Tumor specific methylation of NPY compared to RAS mutation in plasma DNA in the monitoring of colorectal cancer patients treated with last-line regorafenib.

e15541Background: Regorafenib has a proven but small significant effect in refractory colorectal cancer. The objective of the present, post-marketing trial was to investigate the clinical outcome i...